DOI QR코드

DOI QR Code

Preventive Effects of a Major Component of Green Tea, Epigallocathechin-3-Gallate, on Hepatitis-B Virus DNA Replication

  • Karamese, Murat (Department of Microbiology, Medical Faculty, Kafkas University) ;
  • Aydogdu, Sabiha (Department of Microbiology, Medical Faculty, Ataturk University) ;
  • Karamese, Selina Aksak (Department of Histology and Embryology, Medical Faculty, Kafkas University) ;
  • Altoparlak, Ulku (Department of Microbiology, Medical Faculty, Ataturk University) ;
  • Gundogdu, Cemal (Department of Pathology, Medical Faculty, Ataturk University)
  • Published : 2015.06.03

Abstract

Background: Hepatitis B virus infection is one of the major world health problems. Epigallocatechin-3 gallate is the major component of the polyphenolic fraction of green tea and it has an anti-viral, anti-mutagenic, anti-tumorigenic, anti-angiogenic, anti-proliferative, and/or pro-apoptotic effects on mammalian cells. In this study, our aim was to investigate the inhibition of HBV replication by epigallocatechin-3 gallate in the Hep3B2.1-7 hepatocellular carcinoma cell line. Materials and Methods: HBV-replicating Hep3B2.1-7 cells were used to investigate the preventive effects of epigallocatechin-3 gallate on HBV DNA replication. The expression levels of HBsAg and HBeAg were determined using ELISA. Quantitative real-time-PCR was applied for the determination of the expression level of HBV DNA. Results: Cytotoxicity of epigallocathechin-3-gallate was not observed in the hepatic carcinoma cell line when the dose was lower than $100{\mu}M$. The ELISA method demonstrated that epigallocatechin-3 gallate have strong effects on HBsAg and HBeAg levels. Also it was detected by real-time PCR that epigallocatechin-3 gallate could prevent HBV DNA replication. Conclusions: The obtained data pointed out that although the exact mechanism of HBV DNA replication and related diseases remains unclear, epigallocatechin-3 gallate has a potential as an effective anti-HBV agent with low toxicity.

Keywords

Hepatitis B;Hepatocellular carcinoma;EGCG;green tea;in-vitro

Acknowledgement

Supported by : Ataturk University

References

  1. Baumert TF, Thimme R, von Weizsäcker F (2007). Pathogenesis of hepatitis B virus infection. World J Gastroenterol, 13, 82-90. https://doi.org/10.3748/wjg.v13.i1.82
  2. Berkson J (1968). Application of minimum logit chi square estimate to a problem of Grizzle with a notation on the problem of 'no interaction'. Biometrics, 24, 75-95. https://doi.org/10.2307/2528461
  3. Bettuzzi S, Brausi M, Rizzi F, et al (2006). Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a oneyear proof-of-principle study. Cancer Res, 66, 1234-40. https://doi.org/10.1158/0008-5472.CAN-05-1145
  4. Chang LK, Wei TT, Chiu YF, et al (2003). Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate. Biochem Biophys Res Commun, 301, 1062-8. https://doi.org/10.1016/S0006-291X(03)00067-6
  5. Chen L and Zhang HY (2007). Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate. Molecules, 12, 946-57. https://doi.org/10.3390/12050946
  6. Doong SL, Tsai CH, Schinazi RF, et al (1991). Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy- 3'-thiacytidine and related analogues. Proc Natl Acad Sci USA, 88, 8495-9. https://doi.org/10.1073/pnas.88.19.8495
  7. Fassina G, Buffa A, Benelli R, et al (2002). Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS, 16, 939-41. https://doi.org/10.1097/00002030-200204120-00020
  8. Feld J, Locarnini S (2002). Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. J Clin Virol, 25, 267-83. https://doi.org/10.1016/S1386-6532(02)00107-5
  9. Gloro R, Hourmand-Ollivier I, Mosquet B, et al (2005). Fulminant hepatitis during selfmedication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol, 17, 1135-7. https://doi.org/10.1097/00042737-200510000-00021
  10. Harakeh S, Diab-Assaf M, Azar R, et al (2014). Epigallocatechin- 3-gallate inhibits tax-dependent activation of nuclear factor kappa B and of matrix metalloproteinase 9 in human T-cell lymphotropic virus-1 positive leukemia cells. Asian Pac J Cancer Prev, 15, 1219-25. https://doi.org/10.7314/APJCP.2014.15.3.1219
  11. Hastak K, Gupta S, Ahmad N, et al (2003). Role of p53 and NF-${\kappa}B$ in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene, 22, 4851-9. https://doi.org/10.1038/sj.onc.1206708
  12. He W, Li LX, Liao QJ, et al (2011). Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line. World J Gastroenterol, 17, 1507-14. https://doi.org/10.3748/wjg.v17.i11.1507
  13. Hsieh TC and Wu JM (2009). Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res, 29, 4025-32.
  14. Huang HC, Tao MH, Hung TM, et al (2014). (-)-Epigallocatechin- 3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res, 111, 100-111. https://doi.org/10.1016/j.antiviral.2014.09.009
  15. Imanish N, Tuji Y, Katada Y, et al (2002). Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells. Microbiol Immunol, 46, 491-4. https://doi.org/10.1111/j.1348-0421.2002.tb02724.x
  16. Kim M, Kim SY, Lee HW, et al (2013). Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate. Antiviral Res, 100, 460-72. https://doi.org/10.1016/j.antiviral.2013.08.002
  17. Li S, Hattori T, Kodama EN (2011). Epigallocatechin gallate inhibits the HIV reverse transcription step. Antivir Chem Chemother, 21, 239-43. https://doi.org/10.3851/IMP1774
  18. Liu ZS, Tang SL, Ai ZL (2003). Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells. World J Gastroenterol, 9, 1968-71. https://doi.org/10.3748/wjg.v9.i9.1968
  19. Miyata T (2007). Pharmacological basis of traditional medicines and health supplements as curatives. J Pharmacol Sci, 103, 127-31. https://doi.org/10.1254/jphs.CPJ06016X
  20. Mukhtar H and Ahmad N (2000). Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr, 71, 1698-702. https://doi.org/10.1093/ajcn/71.6.1698S
  21. Pang JY, Zhao KJ, Wang JB, et al (2014). Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro. J Zhejiang Univ Sci B, 15, 533-39. https://doi.org/10.1631/jzus.B1300307
  22. Park NH, Song IH, Chung YH (2006). Chronic hepatitis B in hepatocarcinogenesis. J Postgrad Med J, 82, 507-15. https://doi.org/10.1136/pgmj.2006.047431
  23. Perrillo RP (2005). Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis, 25, 20-28. https://doi.org/10.1055/s-2005-915647
  24. Philips BJ, Coyle CH, Morrisroe SN, et al (2009). Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res, 30, 207-15. https://doi.org/10.2220/biomedres.30.207
  25. Qiao Y, Cao J, Xie L, et al (2009). Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch Pharm Res, 32, 1309-15. https://doi.org/10.1007/s12272-009-1917-3
  26. Roh C and Jo SK (2011). (-)-Epigallocatechin gallate inhibits hepatitis C virus (HCV) viral protein NS5B. Talanta, 85, 2639-42. https://doi.org/10.1016/j.talanta.2011.08.035
  27. Tachibana H (2009). Molecular basis for cancer chemoprevention by green tea polyphenol EGCG. Forum Nutr, 61, 156-69. https://doi.org/10.1159/000212748
  28. Tillmann HL (2007). Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol, 13, 125-40. https://doi.org/10.3748/wjg.v13.i1.125
  29. Tseng YP, Kuo YH, Hu CP, et al (2008). The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters. Antiviral Res, 77, 206-214. https://doi.org/10.1016/j.antiviral.2007.12.011
  30. Weber JM., Ruzindana-Umunyana A, Imbeault L, et al (2003). Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res, 58, 167-73. https://doi.org/10.1016/S0166-3542(02)00212-7
  31. Xu J, Wang J, Deng F, et al (2008). Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro. Antiviral Res, 78, 242-9. https://doi.org/10.1016/j.antiviral.2007.11.011
  32. Xu WS, Zhao KK, Miao XH, et al (2010). Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro. World J Gastroenterol, 16, 2028-37. https://doi.org/10.3748/wjg.v16.i16.2028
  33. Ying C, Li Y, Leung CH, et al (2007). Unique anti-viral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci USA, 104, 8526-31. https://doi.org/10.1073/pnas.0609883104
  34. Zhen MC, Wang Q, Huang XH, et al (2007). Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachlorideinduced hepatic fibrosis. J Nutr Biochem, 18, 795-805. https://doi.org/10.1016/j.jnutbio.2006.12.016

Cited by

  1. A Review of the Antiviral Role of Green Tea Catechins vol.22, pp.8, 2017, https://doi.org/10.3390/molecules22081337